Galmed Pharmaceuticals Ltd
GLMD1.630USD
+0.080+5.19%
交易中 （美东）报价延迟15分钟
3.68M总市值
亏损市盈率 TTM
关于 Galmed Pharmaceuticals Ltd 公司
Galmed Pharmaceuticals 是一家位于以色列的临床阶段生物制药公司。该公司的业务重点是开发治疗肝病的疗法。Galmed Pharmaceuticals 的主要产品 Arachmol 是一种针对肝脏的硬脂酰辅酶 A 去饱和酶 1，用于口服治疗 NASH（非酒精性脂肪性肝炎）。
公司简介
公司代码GLMD
公司名称Galmed Pharmaceuticals Ltd
上市日期Mar 13, 2014
CEOMr. Allen Baharaff
员工数量3
证券类型Ordinary Share
年结日Mar 13
公司地址16 Tiomkin Street
城市TEL AVIV-YAFO
上市交易所NASDAQ Capital Market Consolidated
国家Israel
邮编6578317
电话97236938448
网址https://www.galmedpharma.com
公司代码GLMD
上市日期Mar 13, 2014
CEOMr. Allen Baharaff
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
Mr. Amir Poshinski
Mr. Amir Poshinski
Independent Director
Independent Director
3.12K
--
Dr. Carol L. Brosgart, M.D.
Dr. Carol L. Brosgart, M.D.
Independent Director
Independent Director
--
--
Mr. Marshall A. Heinberg, J.D.
Mr. Marshall A. Heinberg, J.D.
Independent Director
Independent Director
--
--
Dr. Liat Hayardeny, Ph.D.
Dr. Liat Hayardeny, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Allen Baharaff
Mr. Allen Baharaff
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
36.94K
+31.44%
Mr. Guy Nehemya
Mr. Guy Nehemya
Chief Operating Officer, Data Protection Officer
Chief Operating Officer, Data Protection Officer
6.28K
+20164.52%
Mr. Yohai Stenzler, CPA
Mr. Yohai Stenzler, CPA
Chief Accounting Officer
Chief Accounting Officer
6.28K
+20164.52%
Mr. Doron Cohen
Mr. Doron Cohen
Chief Financial Officer
Chief Financial Officer
6.25K
+36664.71%
Mr. Shmuel Nir
Mr. Shmuel Nir
Independent Director
Independent Director
3.40K
+1148.16%
Dr. David Sidransky, M.D.
Dr. David Sidransky, M.D.
Lead Independent Director
Lead Independent Director
3.12K
+7338.10%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月1日 周五
更新时间: 8月1日 周五
持股股东
股东类型
持股股东
持股股东
占比
Baharaff (Allen)
0.68%
Schonfeld Strategic Advisors LLC
0.46%
Virtu Americas LLC
0.20%
Two Sigma Investments, LP
0.20%
Cambridge Investment Research Advisors, Inc.
0.19%
Other
98.27%
持股股东
持股股东
占比
Baharaff (Allen)
0.68%
Schonfeld Strategic Advisors LLC
0.46%
Virtu Americas LLC
0.20%
Two Sigma Investments, LP
0.20%
Cambridge Investment Research Advisors, Inc.
0.19%
Other
98.27%
股东类型
持股股东
占比
Individual Investor
1.20%
Hedge Fund
0.66%
Research Firm
0.20%
Investment Advisor
0.19%
Other
97.75%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
36
133.14K
2.44%
+18.75K
2025Q1
40
122.99K
5.45%
+7.20K
2024Q4
44
74.98K
4.98%
+4.09K
2024Q3
46
26.83K
4.31%
-41.91K
2024Q2
47
54.30K
10.41%
+4.14K
2024Q1
52
35.65K
7.07%
-49.52K
2023Q4
54
66.85K
19.98%
-30.97K
2023Q3
59
78.73K
21.96%
+19.78K
2023Q2
57
33.03K
13.93%
-6.52K
2023Q1
63
32.53K
145.11%
-12.28K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baharaff (Allen)
36.94K
1.64%
+8.83K
+31.44%
Mar 21, 2025
Schonfeld Strategic Advisors LLC
25.19K
1.12%
-206.00
-0.81%
Mar 31, 2025
Virtu Americas LLC
11.13K
0.49%
+11.13K
--
Mar 31, 2025
Two Sigma Investments, LP
11.02K
0.49%
+11.02K
--
Mar 31, 2025
Morgan Stanley Smith Barney LLC
7.38K
0.33%
+7.29K
+7435.71%
Mar 31, 2025
Nehemya (Guy)
6.28K
0.28%
+6.25K
+20164.52%
Mar 21, 2025
Stenzler (Yohai)
6.28K
0.28%
+6.25K
+20164.52%
Mar 21, 2025
Cohen (Doron)
6.25K
0.28%
+6.23K
+36664.71%
Mar 21, 2025
Nir (Shmuel)
3.40K
0.15%
+3.12K
+1148.16%
Mar 21, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
公告日期
类型
比率
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
Aug 28, 2024
Merger
12<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
May 12, 2023
Merger
15<1
